Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MicroTherapeutics

This article was originally published in The Gray Sheet

Executive Summary

Liquid embolic system developer secures $56 mil. staged financing from institutional investor Warburg Pincus, the Irvine, California-based company announces May 29. Proceeds will go towards ongoing clinical trials and marketing efforts for the Onyx liquid embolic material, which is delivered through MTI's proprietary microcatheters for the treatment of neurovascular disease, including brain aneurysms and arteriovenous malformations. The equity placement will occur in two stages. The first round, expected to close by the end of the week of May 28, involves the placement of about 2 mil. shares at $3.75 per share, for a total of almost $7.5 mil. before transaction costs. The second stage will involve the offering of approximately 8.1 mil. shares at $6 per share, generating net proceeds of $48.5 mil. If other investors with which MTI already has agreements choose to participate in this financing, proceeds from the second round could increase to as much as $59 mil
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT014967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel